Chembio Diagnostics - 15 Year Stock Price History | CEMI

Historical daily share price chart and data for Chembio Diagnostics since 2004 adjusted for splits and dividends. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. Display 20, 50 and 200 day moving averages and export charts as images to use in articles and blogs. The latest closing price for Chembio Diagnostics as of February 15, 2019 is 6.93.
Chembio Diagnostics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2019 6.7513 5.6600 7.1800 5.4800 6.9300 22.44%
2018 8.7806 8.1000 11.5000 4.9500 5.6600 -30.98%
2017 6.2502 6.6500 8.3500 5.2500 8.2000 20.59%
2016 6.7890 5.2100 9.1200 4.2800 6.8000 27.58%
2015 4.5294 3.8700 5.3400 3.5600 5.3300 36.32%
2014 3.5915 3.4000 4.7300 2.8700 3.9100 16.02%
2013 4.4190 4.7501 5.7100 3.2900 3.3700 -28.75%
2012 4.3034 3.4400 5.2599 3.2800 4.7300 40.77%
2011 3.4753 3.2800 4.5600 2.4800 3.3600 -1.18%
2010 2.1713 2.1600 3.6400 1.5200 3.4000 51.79%
2009 1.3250 0.8800 2.9600 0.6400 2.2400 154.55%
2008 1.3837 1.9200 2.4000 0.6000 0.8800 -59.26%
2007 4.6029 6.1600 7.2000 2.1600 2.1600 -67.47%
2006 5.8140 3.0400 8.2400 2.6400 6.6400 137.14%
2005 4.8378 5.7600 6.5600 2.4400 2.8000 -51.39%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.119B $0.024B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $132.164B 26.13
Medtronic (MDT) Ireland $123.923B 18.53
Stryker (SYK) United States $69.625B 25.56
Boston Scientific (BSX) United States $55.366B 27.03
Baxter (BAX) United States $39.075B 24.08
Zimmer Biomet Holdings (ZBH) United States $25.222B 16.18
Smith & Nephew SNATS (SNN) United Kingdom $16.659B 0.00
ResMed (RMD) United States $14.394B 27.30
Canopy Growth (CGC) Canada $11.042B 0.00
Bio-Rad Laboratories (BIO) United States $8.100B 51.79
Aurora Cannabis (ACB) Canada $7.040B 50.36
Hill-Rom Holdings (HRC) United States $6.974B 21.57
Perrigo (PRGO) Ireland $6.650B 10.09
Insulet (PODD) United States $5.226B 0.00
ICU Medical (ICUI) United States $5.189B 28.91
GW Pharmaceuticals (GWPH) United Kingdom $4.539B 0.00
Haemonetics (HAE) United States $4.489B 39.82
Agios Pharmaceuticals (AGIO) United States $3.449B 0.00
Hutchison China MediTech (HCM) China $3.417B 0.00
Neogen (NEOG) United States $3.281B 50.39
NuVasive (NUVA) United States $3.013B 28.03
National Vision Holdings (EYE) United States $2.624B 50.75
Quidel (QDEL) United States $2.574B 23.28
Aphria (APHA) $2.402B 106.67
NxStage Medical (NXTM) United States $1.954B 0.00
AtriCure (ATRC) United States $1.279B 0.00
Phibro Animal Health (PAHC) United States $1.231B 17.70
VAREX IMAGING (VREX) United States $1.198B 23.45
Cardiovascular Systems (CSII) United States $1.170B 840.00
MacroGenics (MGNX) United States $0.923B 0.00
Cerus (CERS) United States $0.878B 0.00
PetIQ (PETQ) United States $0.837B 21.68
Surmodics (SRDX) United States $0.766B 111.39
Evolus (EOLS) United States $0.747B 0.00
NanoString Technologies (NSTG) United States $0.719B 0.00
Lantheus Holdings (LNTH) United States $0.713B 22.07
Meridian Bioscience (VIVO) United States $0.704B 20.97
OraSure Technologies (OSUR) United States $0.703B 31.03
Omeros (OMER) United States $0.688B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.625B 20.05
Quanterix (QTRX) United States $0.505B 0.00
LeMaitre Vascular (LMAT) United States $0.492B 24.18
Owens & Minor (OMI) United States $0.479B 5.42
TG Therapeutics (TGTX) United States $0.395B 0.00
Insys Therapeutics (INSY) United States $0.368B 0.00
Utah Medical Products (UTMD) United States $0.334B 21.65
BioLife Solutions (BLFS) United States $0.299B 404.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.293B 0.00
Bovie Medical (APYX) United States $0.279B 0.00
Vapotherm (VAPO) United States $0.276B 0.00
Cytosorbents (CTSO) United States $0.262B 0.00
Rockwell Medical (RMTI) United States $0.242B 0.00
Zynex (ZYXI) United States $0.165B 15.97
Surface Oncology (SURF) United States $0.150B 0.00
Fonar (FONR) United States $0.143B 7.65
Chimerix (CMRX) United States $0.101B 0.00
United-Guardian (UG) United States $0.091B 18.98
Female Health (VERU) United States $0.084B 0.00
CAS Medical Systems (CASM) United States $0.070B 0.00
Trinity Biotech (TRIB) Ireland $0.063B 17.33
Conatus Pharmaceuticals (CNAT) United States $0.062B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.056B 0.00
ImmuCell (ICCC) United States $0.038B 0.00
Neurotrope (NTRP) United States $0.034B 0.00
Senestech (SNES) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.013B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.013B 0.00
Akers Biosciences Inc (AKER) United States $0.011B 0.00
Valeritas Holdings (VLRX) United States $0.010B 0.00
Cellectar Biosciences (CLRB) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.007B 13.57